Drug Research

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to a Diagnostic Assay for Non-Alcoholic SteatoHepatitis

LabCorp, a leading global life sciences company, and GENFIT , a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, have announced the signing of a licensing agreement between GENFIT and Covance, LabCorp’s...

Propanc Biopharma Commences Drug Discovery Research Collaboration

Propanc Biopharma, Inc , a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, announced that a cooperation agreement has been entered...

Stem Cell Medicine Licenses Exosome Technology for Treating Autism from Ramot at Tel Aviv University

Stem Cell Medicine Ltd. (SCM), a biotechnology company developing new therapies for neurological indications, including mesenchymal stem cells and anti-BMP molecules for the treatment of Multiple Sclerosis, and gene therapy for the treatment of neuropathic pain, has licensed an...

Injecting New Blood into the Life Sciences Innovation Process

Innovation and collaboration are the lifeblood of the life sciences. Without them, both research and business come to a standstill. Knowing this, how do pharmaceutical and biotechnology companies get the blood pumping, communicate their position to the marketplace as well...

Transforming The Life Sciences Supply Chain Through Blockchain

Imagine the Possibilities: What if innovations in the life sciences supply chain kept up with innovations in medicines and treatments? With many serialization and track & trace regulations in the compliance period, and others (e.g., EU FMD, US DSCSA) on...

The need of innovation in the injectable business – a CDMO perspective

The world of drug development and manufacturing is undergoing a change. Nowhere is this more evident than in the rapid increase in complex compounds such as biologics. This change is further compounded with the erosion of the once commanding ‘blockbuster’...

Speed, Quality and Cost – Leveraging Australia to Expedite Clinical Development

In recent years, the pharmaceutical industry has seen tremendous changes in the way it is expected to deliver new drugs to market: being under increasing pressure to expedite the development of new therapies,to decrease clinical study duration, and to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read